Caris Life Sciences, Inc. (CAI) to Raise $400 Million in IPO

Caris Life Sciences, Inc. (CAI) is planning to raise $400 million in an initial public offering (IPO) on Wednesday, June 18th, IPO Scoop reports. The company will issue 23,500,000 shares at $16.00-$18.00 per share.

In the last 12 months, Caris Life Sciences, Inc. generated $452.5 million in revenue and had a net loss of $248.7 million. Caris Life Sciences, Inc. has a market cap of $5.1 billion.

BofA Securities, J.P. Morgan, Goldman Sachs, Citigroup, TD Cowen, Evercore ISI and Guggenheim Securities acted as the underwriters for the IPO and BTIG and Wolfe Nomura Alliance were co-managers.

Caris Life Sciences, Inc. provided the following description of their company for its IPO: “(Incorporated in Texas)  We are a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer. We develop and commercialize innovative solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Our entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. We founded Caris in 2008 with the belief and vision that combining a vast set of consistently generated molecular information with robust data-driven insights could realize the potential of precision medicine for patients. We have spent the last 17 years developing and building our portfolio of comprehensive, proprietary molecular profiling solutions and generating what we believe to be one of the largest and most comprehensive multi-modal clinico-genomic datasets in oncology based on the more than 6.5 million tests we have run on over 849,000 cases, which have generated measurements of over 38 billion molecular markers. Our platform is purpose-built to leverage the convergence of next-generation sequencing (“NGS”), artificial intelligence (“AI”) and machine learning (“ML”) technologies, and high-performance computing. The power of our differentiated Caris platform has enabled us to develop the latest generation of advanced precision medicine diagnostic solutions designed to address the entire cancer care continuum, including early detection, minimal residual disease (“MRD”) tracking, therapy selection, and treatment monitoring, as well as to create molecular signatures and discover and develop novel precision medicine therapeutics. Our current commercial product portfolio is focused on oncology and consists of MI Profile, our tissue-based molecular profiling solution that has generated the majority of our revenue to date, and Caris Assure, our novel, universal blood-based molecular profiling solution that was broadly launched in the first quarter of 2024 for therapy selection.  Note: Net loss and revenue are for the 12 months that ended March 31, 2025. (Note: Caris Life Sciences, Inc. disclosed its IPO terms – 23.53 million shares at a price range of $16.00 to $18.00 – to raise $400.0 million, if  priced at the $17.00 mid-point, according to its S-1/A filing on June 9, 2025. Background: Caris Life Sciences, Inc. filed its S-1 for its IPO on May 23, 2025, without disclosing the terms. Estimated IPO proceeds are $100.0 million, a placeholder figure. Some IPO pros, however, believe that this IPO could raise between $150 million and $300 million.) “.

Caris Life Sciences, Inc. was founded in 2008 and has 1769 employees. The company is located at 750 W. John Carpenter Freeway Suite 800 Irving, TX 75039 Telephone: (866) 771-8946 and can be reached via phone at (866) 771-8946 or on the web at http://www.carislifesciences.com/.